Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
Crossref DOI link: https://doi.org/10.1186/1471-2407-14-521
Published Online: 2014-07-19
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Folprecht, Gunnar
Hamann, Susanne
Schütte, Katharina
Trarbach, Tanja
Stoehlmacher-Williams, Jan
Ehninger, Gerhard
License valid from 2014-07-19